Back to Search
Start Over
[Questions--answers on the use of rivaroxaban for the treatment of venous thromboembolic disease].
- Source :
-
Journal des maladies vasculaires [J Mal Vasc] 2012 Dec; Vol. 37 (6), pp. 300-10. Date of Electronic Publication: 2012 Nov 02. - Publication Year :
- 2012
-
Abstract
- Rivaroxaban is a direct oral anticoagulant targeting factor Xa. Efficacy and safety of rivaroxaban were evaluated through the phase 3 EINSTEIN program, consisting in three clinical trials regarding the treatment of deep vein thrombosis (EINSTEIN DVT), pulmonary embolism (EINSTEIN PE), and in secondary prevention after a first episode of venous thromboembolic disease (EISNTEIN EXT). Rivaroxaban was recently approved both by the European and the French Health agencies for the treatment of DVT and prevention of deep vein thrombosis recurrence. This report addresses the use of rivaroxaban in clinical practice in such indications.<br /> (Copyright © 2012 Elsevier Masson SAS. All rights reserved.)
- Subjects :
- Age Factors
Drug Interactions
Factor Xa
France
Hemorrhage chemically induced
Humans
Morpholines adverse effects
Morpholines pharmacology
Risk Factors
Rivaroxaban
Thiophenes adverse effects
Thiophenes pharmacology
Vitamins antagonists & inhibitors
Anticoagulants therapeutic use
Morpholines therapeutic use
Pulmonary Embolism drug therapy
Thiophenes therapeutic use
Venous Thromboembolism drug therapy
Venous Thrombosis drug therapy
Subjects
Details
- Language :
- French
- ISSN :
- 2214-8116
- Volume :
- 37
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Journal des maladies vasculaires
- Publication Type :
- Academic Journal
- Accession number :
- 23122646
- Full Text :
- https://doi.org/10.1016/j.jmv.2012.09.003